Follicular lymphoma - rituximab (review) (TA243)
Fast, easy summary view of NICE guidance on 'blood and bone marrow cancers'
This guidance updates and replaces NICE technology appraisal 110 (published in September 2006).
NICE recommends rituximab in combination with certain chemotherapies as a possible treatment for people with stage III–IV follicular lymphoma who haven’t been treated before (first-line treatment). Your doctor should talk to you about which chemotherapies can be used in combination with rituximab.
Who can have rituximab?
You should be able to have rituximab if all of the following apply:
- you have symptoms
- you have not had treatment before.
NICE has produced separate guidance on when rituximab can be offered to people with stage III–IV follicular lymphoma who have been treated before.
Why has NICE said this?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS.
NICE recommended rituximab in combination with certain chemotherapies because it works better than other treatments available on the NHS. Although it costs more than some other treatments, this was justified by the additional benefits it provided.
Visit the NICE Pathway: blood and bone marrow cancers
- None found
This page was last updated: 13 February 2014
- Web format
- Full Guidance (PDF)
- TA243 Rituximab ar gyfer triniaeth llinell flaen lymffoma ffoliglaidd cam III-IV: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.